Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 3/2018

01-06-2018 | Research Article

Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET

Authors: Hongzan Sun, Jun Xin, Jinyuan Zhou, Zaiming Lu, Qiyong Guo

Published in: Molecular Imaging and Biology | Issue 3/2018

Login to get access

Abstract

Purpose

The purpose of this study is to evaluate the diagnostic concordance and metric correlations of amide proton transfer (APT) imaging with gadolinium-enhanced magnetic resonance imaging (MRI) and 2-deoxy-2-[18F-]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET), using hybrid brain PET/MRI.

Procedures

Twenty-one subjects underwent brain gadolinium-enhanced [18F]FDG PET/MRI prospectively. Imaging accuracy was compared between unenhanced MRI, MRI with enhancement, APT-weighted (APTW) images, and PET based on six diagnostic criteria. Among tumors, the McNemar test was further used for concordance assessment between gadolinium-enhanced imaging, APT imaging, and [18F]FDG PET. As well, the relation of metrics between APT imaging and PET was analyzed by the Pearson correlation analysis.

Results

APT imaging and gadolinium-enhanced MRI showed superior and similar diagnostic accuracy. APTW signal intensity and gadolinium enhancement were concordant in 19 tumors (100 %), while high [18F]FDG avidity was shown in only 12 (63.2 %). For the metrics from APT imaging and PET, there was significant correlation for 13 hypermetabolic tumors (P < 0.05) and no correlation for the remaining six [18F]FDG-avid tumors.

Conclusions

APT imaging can be used to increase diagnostic accuracy with no need to administer gadolinium chelates. APT imaging may provide an added value to [18F]FDG PET in the evaluation of tumor metabolic activity during brain PET/MR studies.
Literature
1.
Fraum TJ, Fowler KJ, McConathy J (2016) PET/MRI:: emerging clinical applications in oncology. Acad Radiol 23:220–236CrossRefPubMed
2.
Spick C, Herrmann K, Czernin J (2016) 18F-FDG PET/CT and PET/MRI perform equally well in cancer patients: evidence from studies on more than 2300 patients. J Nucl Med 57:420–430CrossRefPubMedPubMedCentral
3.
Ishii S, Shimao D, Hara T et al (2016) Comparison of integrated whole-body PET/MR and PET/CT: is PET/MR alternative to PET/CT in routine clinical oncology? Ann Nucl Med 30:225–233CrossRefPubMed
4.
Padhani AR, Liu G, Mu-Koh D et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125CrossRefPubMedPubMedCentral
5.
Yang D, Korogi Y, Sugahara T et al (2002) Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44:656–666CrossRefPubMed
6.
Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC (2003) Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 9:1085–1090CrossRefPubMed
7.
8.
Harston GW, Tee YK, Blockley N et al (2015) Identifying the ischaemic penumbra using pH-weighted magnetic resonance imaging. Brain 138:36–42CrossRefPubMed
9.
Sun H, Xin J, Zhang S et al (2014) Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging 41:898–905CrossRefPubMed
10.
Han M, Kim SY, Lee SJ, Choi JW (2015) The correlations between MRI perfusion, diffusion parameters, and 18F-FDG PET metabolic parameters in primary head-and-neck cancer: a cross-sectional analysis in single institute. Medicine (Baltimore) 94:e2141CrossRef
11.
Zhou J, Blakeley JO, Hua J et al (2008) Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med 60:842–849CrossRefPubMedPubMedCentral
12.
Jiang S, Yu H, Wang X et al (2016) Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla. Eur Radiol 26:64–71CrossRefPubMed
13.
Kickingereder P, Wiestler B, Sahm F et al (2014) Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 272:843–850CrossRefPubMed
14.
Padma MV, Said S, Jacobs M et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neuro-Oncol 64:227–237CrossRef
15.
Klenk C, Gawande R, Tran VT et al (2016) Progressing toward a cohesive pediatric 18F-FDG PET/MR protocol: is administration of gadolinium chelates necessary? J Nucl Med 57:70–77CrossRefPubMed
16.
Goerke S, Zaiss M, Kunz P et al (2015) Signature of protein unfolding in chemical exchange saturation transfer imaging. NMR Biomed 28:906–913CrossRefPubMed
17.
Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50:1120–1126CrossRefPubMed
18.
Jones CK, Schlosser MJ, van Zijl PC et al (2006) Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med 56:585–592CrossRefPubMed
19.
Zhou J, Tryggestad E, Wen Z et al (2011) Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 17:130–134CrossRefPubMed
20.
Togao O, Yoshiura T, Keupp J et al (2014) Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro-Oncology 16:441–448CrossRefPubMed
21.
Park KJ, Kim HS, Park JE et al (2016) Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur Radiol 26:4390–4403CrossRefPubMed
22.
Sakata A, Okada T, Yamamoto A et al (2015) Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neuro-Oncol 122:339–348CrossRef
23.
Ramalho J, Semelka RC, Ramalho M et al (2016) Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 37:1192–1198CrossRefPubMed
24.
Thomsen HS, Morcos SK, Almen T et al (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 23:307–318CrossRefPubMed
25.
26.
Lee JW, Kang KW, Park SH et al (2009) 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 36:1574–1582CrossRefPubMed
27.
Zhou J, Zhu H, Lim M et al (2013) Three-dimensional amide proton transfer MR imaging of gliomas: initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging 38:1119–1128CrossRefPubMed
28.
Zhu H, Jones CK, van Zijl PC, Barker PB, Zhou J (2010) Fast 3D chemical exchange saturation transfer (CEST) imaging of the human brain. Magn Reson Med 64:638–644CrossRefPubMedPubMedCentral
29.
Zhao X, Wen Z, Zhang G et al (2013) Three-dimensional turbo-spin-echo amide proton transfer MR imaging at 3-Tesla and its application to high-grade human brain tumors. Mol Imaging Biol 15:114–122CrossRefPubMedPubMedCentral
30.
31.
32.
Rivlin M, Horev J, Tsarfaty I, Navon G (2013) Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep 3:3045CrossRefPubMed
Metadata
Title
Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET
Authors
Hongzan Sun
Jun Xin
Jinyuan Zhou
Zaiming Lu
Qiyong Guo
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 3/2018
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-017-1136-0

Other articles of this Issue 3/2018

Molecular Imaging and Biology 3/2018 Go to the issue

Correction

Correction to: LyP-1 Conjugated Nanoparticles for Magnetic Resonance Imaging of Triple Negative Breast Cancer

Research Article

Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model

Letter to the Editor

Letter to the Editor re: Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

Commentary

Translating Molecular Imaging of the Vulnerable Plaque—a Vulnerable Project?

Letter to the Editor

Response to Notter and Meyer’s Letter to the Editor Regarding Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

Research Article

Single-Cell Imaging Using Radioluminescence Microscopy Reveals Unexpected Binding Target for [18F]HFB